#United States #Bridgewater #Insmed #Paul Hudson #Utpal Koppikar

Insmed Strengthens Leadership with New Board Members

Insmed Incorporated, a biopharmaceutical company dedicated to improving the lives of patients with serious diseases, has announced the appointment of Paul Hudson and Utpal Koppikar as new independent directors to its Board. This strategic move comes as the company seeks to enhance its growth trajectory and expand its innovative therapies portfolio. Both directors bring a wealth of experience that aligns well with Insmed's mission and strategic goals.

Expertise of Paul Hudson

Paul Hudson is best known for his impactful leadership roles in major pharmaceutical companies. Before joining Insmed, he held the position of Chief Executive Officer (CEO) at Sanofi S.A. from September 2019 to February 2026, where he played a crucial role in transforming the organization. Hudson also served as CEO of Novartis Pharmaceuticals, significantly contributing to their global strategy from 2016 to 2019. His extensive career includes key positions in AstraZeneca, where he was the President of AstraZeneca United States, and various roles in sales and marketing with prominent firms like Schering-Plough and GlaxoSmithKline.

Hudson commented on his appointment, stating, "Insmed is a company I have admired for years. I look forward to leveraging my experience to support Insmed's continued growth."

Financial Acumen of Utpal Koppikar

Joining Hudson is Utpal Koppikar, a seasoned leader in biopharma finance. Currently serving as Chief Financial Officer (CFO) at Verily Health, he possesses a strong track record in driving financial success across various biopharma stages. His previous tenure as CFO at Atara Biotherapeutics and senior roles at Gilead Sciences and Amgen highlight his expertise in navigating financial complexities in the biopharmaceutical sector.

Upon joining Insmed's Board, Koppikar expressed enthusiasm, saying, "Insmed's commercial momentum and people-first culture create a compelling organization. I'm eager to help steer the financial and operational strategies as we work to deliver transformative therapies to patients."

Strategic Implications for Insmed

The addition of Hudson and Koppikar is expected to significantly enhance Insmed's strategic capabilities. Will Lewis, the Chair and CEO of Insmed, stated, "Paul and Utpal are exceptional additions to our board. Their experiences will be invaluable as we continue to execute our global growth strategy and build long-term shareholder value."

As Insmed advances its portfolio focused on serious and rare diseases, these appointments come at a crucial time. The company is committed to delivering cutting-edge therapies for chronic, debilitating conditions, as evidenced by its diverse pipeline which includes approved therapies and investigational medicines.

Insmed's Broader Mission

Headquartered in Bridgewater, New Jersey, Insmed is dedicated to innovating therapeutic options across several areas, including respiratory, immunology, and other rare diseases. By leveraging advanced technologies in drug discovery and research, such as gene therapy and AI-driven techniques, Insmed aspires to fulfill its mission of transformative care for patients who suffer from serious illnesses.

With their combined experience, Hudson and Koppikar will not only contribute to the strategic goals of Insmed but also bolster the company's standing in the competitive biopharmaceutical landscape. This strategic development represents a forward-thinking approach to governance, aligning with the company’s intentions to drive innovation and expand its global reach in patient care.

As Insmed navigates this exciting new chapter, stakeholders can anticipate valuable contributions from its distinguished board members that will shape the future of biopharmaceutical advancements and patient support services.

For more information on Insmed and its initiatives, visit Insmed's website.